At a glance
ClinicalIndex Comparison RecordN/ACompleted· 143 enrolled
Drug / intervention
Influenza vaccinationbiological
Likely dose
Influenza vaccination 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitor
In Brief
A clinical study evaluating Influenza vaccination for Influenza and Solid Carcinoma. Completed, enrolled 143 participants across 1 site.
Detailed Summary
The purpose of this study is to elucidate efficacy and safety of influenza vaccine in cancer patients receiving immune checkpoint inhibitor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Solid Carcinoma
CountriesSouth Korea
CollaboratorsGreen Cross Corporation
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartSep 2018
Primary CompletionDec 2018
Study CompletionMay 2019
TodayJul 2026
First PostedJul 18, 2018
Enrollment StartSep 1, 2018
Primary CompletionDec 21, 2018
Study CompletionMay 30, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.0 years ago
Interventions
Influenza vaccinationbiological
Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM